Pfizer Inc., a leading global biopharmaceutical company headquartered in the United States, has been at the forefront of medical innovation since its founding in 1849. With a strong presence in North America, Europe, and Asia, Pfizer operates across various sectors, including vaccines, oncology, and rare diseases. The company is renowned for its core products, such as the COVID-19 vaccine and groundbreaking cancer therapies, which leverage advanced biotechnology to address unmet medical needs. Pfizer's commitment to research and development has positioned it as a market leader, consistently achieving significant milestones in drug discovery and patient care. With a robust portfolio and a reputation for quality, Pfizer continues to shape the future of healthcare, making a profound impact on global health outcomes.
How does Pfizer's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pfizer's score of 77 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Pfizer reported significant greenhouse gas emissions, with total Scope 1 emissions at approximately 620,124,000 kg CO2e and Scope 2 emissions at about 486,384,000 kg CO2e. The company has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 emissions by 46% from a 2019 baseline by 2030. Additionally, Pfizer is committed to achieving net-zero emissions by 2040, targeting a 95% reduction in Scope 1 emissions and a 90% reduction in Scope 3 emissions, which encompass its entire value chain. Pfizer's near-term targets include a 25% reduction in Scope 3 emissions from business travel by 2025 and a 10% reduction in upstream transportation and distribution emissions by the same year. The company also aims to increase its annual sourcing of renewable electricity from 9% in 2019 to 100% by 2030. Furthermore, Pfizer has committed that 64% of its suppliers, by spend, will have science-based targets by 2025. These initiatives reflect Pfizer's dedication to addressing climate change and reducing its carbon footprint, aligning with global efforts to limit temperature rise to 1.5°C.
Access structured emissions data, company-specific emission factors, and source documents
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pfizer is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.